Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations.
Pudelko L, Jaehrling F, Reusch C, Vitri S, Stroh C, Linde N, Sanderson MP, Musch D, Lebrun CJ, Keil M, Esdar C, Blaukat A, Rosell R, Schumacher KM, Karachaliou N. Pudelko L, et al. Among authors: karachaliou n. iScience. 2020 Nov 20;23(12):101832. doi: 10.1016/j.isci.2020.101832. eCollection 2020 Dec 18. iScience. 2020. PMID: 33305187 Free PMC article.
Overcoming MET-mediated resistance in oncogene-driven NSCLC.
Reischmann N, Schmelas C, Molina-Vila MÁ, Jordana-Ariza N, Kuntze D, García-Roman S, Simard MA, Musch D, Esdar C, Albers J, Karachaliou N. Reischmann N, et al. Among authors: karachaliou n. iScience. 2023 May 29;26(7):107006. doi: 10.1016/j.isci.2023.107006. eCollection 2023 Jul 21. iScience. 2023. PMID: 37534190 Free PMC article.
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.
F Smit E, Dooms C, Raskin J, Nadal E, Tho LM, Le X, Mazieres J, S Hin H, Morise M, W Zhu V, Tan D, H Holmberg K, Ellers-Lenz B, Adrian S, Brutlach S, Schumacher KM, Karachaliou N, Wu YL. F Smit E, et al. Among authors: karachaliou n. Future Oncol. 2022 Mar;18(9):1039-1054. doi: 10.2217/fon-2021-1406. Epub 2021 Dec 17. Future Oncol. 2022. PMID: 34918545 Free article.
Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines.
Codony-Servat J, Viteri S, Codony-Servat C, Ito M, Bracht JWP, Berenguer J, Chaib I, Molina-Vila MA, Karachaliou N, Rosell R. Codony-Servat J, et al. Among authors: karachaliou n. Transl Lung Cancer Res. 2019 Aug;8(4):340-351. doi: 10.21037/tlcr.2019.08.22. Transl Lung Cancer Res. 2019. PMID: 31555510 Free PMC article.
Mechanisms of resistance to osimertinib.
Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Lazzari C, et al. Among authors: karachaliou n. J Thorac Dis. 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30. J Thorac Dis. 2020. PMID: 32642198 Free PMC article. Review.
Novel molecular targets for the treatment of lung cancer.
Rosell R, Karachaliou N, Arrieta O. Rosell R, et al. Among authors: karachaliou n. Curr Opin Oncol. 2020 Jan;32(1):37-43. doi: 10.1097/CCO.0000000000000590. Curr Opin Oncol. 2020. PMID: 31599770 Review.
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.
Santarpia M, Aguilar A, Chaib I, Cardona AF, Fancelli S, Laguia F, Bracht JWP, Cao P, Molina-Vila MA, Karachaliou N, Rosell R. Santarpia M, et al. Among authors: karachaliou n. Cancers (Basel). 2020 Jun 5;12(6):1475. doi: 10.3390/cancers12061475. Cancers (Basel). 2020. PMID: 32516941 Free PMC article. Review.
194 results